Molecular Testing for Red Cell Antigens in the Setting of Transplant or Chimerism

Please note: AABB reserves the right to make updates to this program.

This on-demand eCast is complimentary to AABB members.

Recording Program Date: Wednesday, June 3, 2020 - On-Demand Available

Master Program Number: 20EL-540

  • Educational Track: Technical/Clinical
  • Topic: Patient Transfusion
  • Intended Audience: CEOs, CFOs, COOs, Directors, Facilities that perform molecular testing, Hospital Blood Banks, Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Basic, Intermediate
  • Director: Lisa M. Shave MS, MLS(ASCP)CMSBBCM, Medical Laboratory Technology Program Coordinator & Professor, Mercer County Community College, West Windsor, NJ; Medical Laboratory Scientist, Pennsylvania Hospital, Philadelphia, PA
    Speaker: Margaret A. Keller, PhD, Senior Director, National Molecular Laboratory, American Red Cross, Philadelphia, PA
  • Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Describe how molecular testing is used to determine blood group antigen phenotypes.
    • Describe how stem cell transplant or chimerism can complicate red cell phenotyping.
    • Describe how red cell alloimmunization can impact decision making and planning around hematopoietic stem cell transplant.
    • Use case studies to illustrate the challenges of phenotyping in these scenarios.

    Program Description

    Molecular testing for blood group antigen phenotypes is becoming a commonly used in the toolbox of transfusion medicine, especially in patient populations with high alloimmunization rates, including those with hemoglobinopathies. The ability to phenotype using serology or molecular methods can be hampered by chimerism whether natural or due to incomplete engraftment. In addition, availability of blood products for the pre-transplant period and the time immediately following the transplant for patients who are highly alloimmunized can add another barrier to life-saving treatment. Cases will be used to illustrate these points.


    This eCast is complimentary to AABB individual members; regular eCast registration fees apply for non-AABB members. Registration is required for nonmembers; AABB individual members may register for the program but access is automatically provided via the Education Platform at http://education.aabb.org under the AABB Member Benefit Learning Programs section (within “On-Demand eCasts” in the “My Learning Programs” section).

    Program #
    Single Viewer: On-Demand Register 20EL-540-4035

    Continuing Education Credit

    AABB designates the on-demand eCast eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

    Speaker Biography

    Dr. Margaret Keller is the Senior Director of the AABB accredited American Red Cross National Molecular Laboratory in Philadelphia where she is involved in both donor and patient testing for red blood cell and platelet antigens. She is adjunct Associate Professor at Thomas Jefferson University. Margaret Keller received her PhD in molecular genetics from the University of Pennsylvania. She is American Rare Donor Program liaison to the Molecular Testing Standards Unit of the AABB and a member of the ISBT Working Party on Blood Group Allele Terminology and Immunogenetics. She is molecular editor of the journal Immunohematology.